利用放射敏感性与正常组织毒性的基因组标志物个体化非小细胞肺癌放疗处方剂量
该文提出放射肿瘤学领域沿用「所有患者生物学相似、对相同剂量放疗反应一致」的过时零假设,利用基因组校正放疗剂量(GARD)方法结合肿瘤控制概率与正常组织并发症概率的竞争风险数学模型,个体化优化放疗剂量。基于两个前瞻性非小细胞肺癌(NSCLC)队列数据验证该模型可预测RTOG 0617结果,并解释该试验失败源于经验性统一剂量递增的生物学不精确性,导致80%患者正常组织过度暴露而无潜在肿瘤控制获益。
要点
- 经验性统一放疗剂量对多数患者存在过度或不足照射。
- GARD结合竞争风险模型可同时优化肿瘤控制与毒性。
- 模型预测RTOG 0617结果,80%患者正常组织过度暴露。
核心结论
- 数据揭示放射敏感性异质性,提供解释经验性放疗剂量递增失败的生物学框架。
- 将基因组学纳入放疗可量化改善肺癌临床结局的机会。
研究设计与样本
- 研究使用先前开发的基因组校正放疗剂量(GARD)方法。
- 开发结合肿瘤控制概率与正常组织并发症概率经典方程的患者特异性竞争风险数学模型。
- 使用两个前瞻性收集的NSCLC患者队列数据验证竞争风险模型。
主要发现
- 竞争风险模型预测了RTOG 0617的结果。
- RTOG 0617失败可由经验性统一剂量递增的生物学不精确性解释。
- 经验性统一剂量递增导致80%患者正常组织过度暴露于毒性而无潜在肿瘤控制获益。
临床怎么用
- 可利用患者特异性基因组信息个体化优化放疗剂量,同时兼顾肿瘤控制与正常组织毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Cancer sequencing efforts have revealed that cancer is the most complex and heterogeneous disease that affects humans. However, radiation therapy (RT), one of the most common cancer treatments, is prescribed on the basis of an empirical one-size-fits-all approach. We propose that the field of radiation oncology is operating under an outdated null hypothesis: that all patients are biologically similar and should uniformly respond to the same dose of radiation. METHODS: We have previously developed the genomic-adjusted radiation dose, a method that accounts for biological heterogeneity and can be used to predict optimal RT dose for an individual patient. In this article, we use genomic-adjusted radiation dose to characterize the biological imprecision of one-size-fits-all RT dosing schemes that result in both over- and under-dosing for most patients treated with RT. To elucidate this inefficiency, and therefore the opportunity for improvement using a personalized dosing scheme, we develop a patient-specific competing hazards style mathematical model combining the canonical equations for tumor control probability and normal tissue complication probability. This model simultaneously optimizes tumor control and toxicity by personalizing RT dose using patient-specific genomics. RESULTS: Using data from two prospectively collected cohorts of patients with NSCLC, we validate the competing hazards model by revealing that it predicts the results of RTOG 0617. We report how the failure of RTOG 0617 can be explained by the biological imprecision of empirical uniform dose escalation which results in 80% of patients being overexposed to normal tissue toxicity without potential tumor control benefit. CONCLUSIONS: Our data reveal a tapestry of radiosensitivity heterogeneity, provide a biological framework that explains the failure of empirical RT dose escalation, and quantify the opportunity to improve clinical outcomes in lung cancer by incorporating genomics into RT.
引用
- Scott JG, Sedor G, Scarborough JA, et al. Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in NSCLC. J Thorac Oncol. 2020. PMID: 33301984. doi:10.1016/j.jtho.2020.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。